All three requested consequence/LOF criteria are not applicable: the variant is a BRCA1 missense substitution, and ENIGMA v1.2 excludes PVS1, PM4, and BP3 for this consequence class. The governing ENIGMA BRCA1/2 V1.2 framework controls all five requested criteria. No requested criterion is met: PS1 lacks a pathogenic same-amino-acid comparator, while PM1, PM5, PP2, and BP1 are not applicable under explicit VCEP rules. The only same-residue alternate found in the governing functional tables, p.Glu1494Lys, is classified as no functional impact/Not Pathogenic. PS2 and PM6 are not applicable under the governing ENIGMA BRCA1/2 VCEP specification. PP1 and BS4 remain not assessed because no variant-specific segregation or non-segregation evidence was available; the clinical-history LR row was not used as a segregation result. Neither PS3 nor BS3 is assessed because the governing ENIGMA variant-specific functional-assay resources contain no entry for NM_007294.4:c.4481A>G (p.Glu1494Gly/p.E1494G), and no separate variant-specific protein-function assay evidence was available in the case bundle. For this missense variant, the governing ENIGMA specification was used first. PS4 lacks required case-control statistics; PP4 and BP5 use the exact Li clinical-history LR of 1.098592032317503, which is below pathogenic-supporting and above benign-supporting thresholds; PP5 and BP6 are excluded by ENIGMA and lack eligible ClinVar expert-panel classifications. The variant is missense, so PP3 and BP4 were assessed through the REVEL protein-impact path only; BP7 is not applicable. REVEL 0.492 is below the supporting PP3 threshold of 0.644 and above the supporting BP4 threshold of 0.29, so neither computational code is met.